Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma.
Kostopoulos IV, Ntanasis-Stathopoulos I, Rousakis P, Malandrakis P, Panteli C, Eleutherakis-Papaiakovou E, Angelis N, Spiliopoulou V, Syrigou RE, Bakouros P, Dimitrakopoulou G, Fotiou D, Migkou M, Kanellias N, Paschalidis N, Gavriatopoulou M, Kastritis E, Dimopoulos MA, Tsitsilonis OE, Terpos E. Kostopoulos IV, et al. Among authors: syrigou re. Am J Hematol. 2024 Jun 11. doi: 10.1002/ajh.27414. Online ahead of print. Am J Hematol. 2024. PMID: 38860642
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Spiliopoulou V, Kostopoulos IV, Syrigou RE, Eleutherakis-Papaiakovou E, Gkolfinopoulos S, Tsitsilonis OE, Kastritis E, Dimopoulos MA. Terpos E, et al. Among authors: syrigou re. Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284347. Online ahead of print. Haematologica. 2024. PMID: 38356458 Free article.
Management and Outcomes of Anti-CD38 Refractory Patients: The Impact of Retreatment and of Subsequent Therapies.
Kastritis E, Theodorakakou F, Ntanasis-Stathopoulos I, Spiliopoulou V, Solia E, Malandrakis P, Syrigou R, Kokkali N, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Roussou M, Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: syrigou r. Hemasphere. 2023 Nov 3;7(11):e975. doi: 10.1097/HS9.0000000000000975. eCollection 2023 Nov. Hemasphere. 2023. PMID: 37936678 Free PMC article. No abstract available.
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.
Ntanasis-Stathopoulos I, Filippatos C, Gavriatopoulou M, Malandrakis P, Eleutherakis-Papaiakovou E, Spiliopoulou V, Syrigou RE, Theodorakakou F, Fotiou D, Migkou M, Roussou M, Kastritis E, Dimopoulos MA, Terpos E. Ntanasis-Stathopoulos I, et al. Among authors: syrigou re. Diseases. 2023 Sep 18;11(3):123. doi: 10.3390/diseases11030123. Diseases. 2023. PMID: 37754319 Free PMC article.
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes.
Kastritis E, Gavriatopoulou M, Solia E, Theodorakakou F, Spiliopoulou V, Malandrakis P, Ntanasis-Stathopoulos I, Migkou M, Kokkali N, Eleutherakis-Papaiakovou E, Syrigou R, Fotiou D, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: syrigou r. Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):844-849. doi: 10.1016/j.clml.2023.07.013. Epub 2023 Aug 1. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37599164
Remnant cholesterol and atherosclerotic disease in high cardiovascular risk patients. Beyond LDL cholesterol and hypolipidemic treatment.
Delialis D, Georgiopoulos G, Aivalioti E, Mavraganis G, Dimopoulou AM, Sianis A, Aggelidakis L, Patras R, Petropoulos I, Ioannou S, Syrigou R, Chatzidou S, Kanakakis I, Stellos K, Stamatelopoulos K. Delialis D, et al. Among authors: syrigou r. Hellenic J Cardiol. 2022 Jul-Aug;66:26-31. doi: 10.1016/j.hjc.2022.05.011. Epub 2022 Jun 4. Hellenic J Cardiol. 2022. PMID: 35667617 Free article.